
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
A clinical oncology update on managing primary liver cancer (HCC), detailing BCLC staging, IMbrave150 immunotherapy (Atezolizumab + Bevacizumab), anti-VEGF management of variceal bleeding, tyrosine kinase inhibitors (Lenvatinib, Cabozantinib), and liver resection thresholds.
CRITICAL CLINICAL RED FLAG: Patients with known chronic hepatitis B/C or cirrhosis who develop dull right upper quadrant abdominal fullness, unprovoked ascites, or rapid elevation of serum Alpha-Fetoprotein (AFP) require immediate multiphasic liver CECT or Primovist MRI.
Hepatocellular Carcinoma arises in the setting of chronic hepatic fibrosis and cirrhosis in >80% of cases. Treatment choice is dictated by liver functional reserve (Child-Pugh Score A vs B) alongside the Barcelona Clinic Liver Cancer (BCLC) algorithm.
BCLC 0/A (Early Stage): Solitary nodule <=5 cm or <=3 nodules <=3 cm with preserved Child-Pugh A β candidates for radical surgical resection or microwave ablation.
BCLC B (Intermediate Stage): Multinodular asymptomatic disease without vascular invasion β managed with Transarterial Chemoembolization (TACE) or systemic therapy.
BCLC C (Advanced Stage): Portal vein invasion or extrahepatic spread β candidates for frontline systemic immunotherapy.
The phase III IMbrave150 trial supplanted multi-kinase inhibitors (Sorafenib) as frontline therapy:
Atezolizumab (anti-PD-L1) + Bevacizumab (anti-VEGF): Achieved an overall survival exceeding 19.2 months with an objective response rate of 30%.
Durvalumab + Tremelimumab (STRIDE Regimen - HIMALAYA Trial): Dual checkpoint blockade offering a non-VEGF frontline alternative for patients with high bleeding risk.
Lenvatinib: An effective oral TKI alternative demonstrating non-inferior overall survival and high tumor shrinkage rates.
"The combination of immune checkpoint inhibition and anti-angiogenesis has doubled median overall survival in advanced liver cancer, transforming a historically lethal disease." β Dr. Neha Gupta

Rigorous home blood pressure monitoring (target <140/90 mmHg) and routine urine dipstick analysis for proteinuria (grade >=2 requiring dose interruption) are essential components of safe outpatient delivery.
CLINICAL CAUTION: Upper GI endoscopy must be performed within 6 months prior to initiating Bevacizumab in HCC patients to treat high-risk esophageal varices and avoid catastrophic gastrointestinal bleeding.
For patients with progressive disease post-immunotherapy, second-line options include Cabozantinib, Regorafenib (for prior sorafenib responders), and Ramucirumab (for patients with baseline AFP >=400 ng/mL).
1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (IMbrave150) β NEJM, 2020; 382: 1894-1905.
2. Tremelimumab plus Durvalumab in Advanced Hepatocellular Carcinoma (HIMALAYA Trial) β Lancet Oncol, 2022; 23(10): 1310-1323.

Senior Consultant & Clinical Director β Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica β Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare β Bone and Cancer Institute, Bathinda β is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists β Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) β guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director β Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director β Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director β Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare β Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.